Skadden is representing Theravance Inc. (as co-counsel) in its $1 billion royalty participation agreement with Elan Corporation, plc, announced on May 13. Under the deal, Elan will purchase a 21 percent participation interest in future royalty payments related to four respiratory drug programs partnered with GlaxoSmithKline plc.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates